Roche Holdings(OTCMKTS:RHHBY) revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. The companys oncology drugs will account for 45% of the companys total sales in 2020, but Neuroscience drugs are key to the near term revenue growth, in our view.Oncology drugs are expected to be the single-biggest revenue driver with $30.1 billion in revenues (45% of Total Revenues), which is 5.7x the size of its Neuroscience drugs revenue in 2020. Neuroscience drugs revenues, which includes Ocrevus and Modopar among other drugs, will be the fastest-growing segment adding $3.7 billion over 2017-2020 (32% of $11.6 billion in incremental revenues). Oncology drugs revenues, which includes Herceptin, Perjeta, Tecentriq, and Avastin among other drugs, will add about $3.4 billion over 2017-2020 (29% of the $11.6 billion in incremental revenue). Look at our interactive dashboard analysis on Roches Revenues for more details, parts of which are highlighted below.

Roches Revenue Has Been On A Rise Over The Last Few Years

Comparing Roches Sales Growth To Its Peers

Roche Has One of The Largest Oncology Drugs Portfolio, But It Is Expected To See A Decline Going Forward.

Ocrevus Has Been The Best Drug Launch Ever For Roche, Boosting Its Neuroscience Drugs Portfolio

Other Therapeutic Drugs Could Also See Growth In The Near Term

Among Other Segments, In-Vitro Diagnostics Could Continue To Grow At A Steady Pace, While Immunology, Ophthalmology, And Virology Drugs Could See A Decline

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams|Product, R&D, and Marketing Teams

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more:
Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience - Nasdaq